Kailera Therapeutics initiated with an Outperform at William Blair

William Blair analyst Andy Hsieh initiated coverage of Kailera Therapeutics (KLRA) with an Outperform rating. Kailera is advancing a pipeline of GLP-1-based weight loss therapies that could address patients across the spectrum of overweight and obese body mass indexes, the analyst tells investors in a research note. Blair says that with the company’s mechanisms either clinically or commercially validated, its clinical and regulatory risk are largely mitigated.